

ANCO FAX News

Association of Northern California Oncologists
Post Office Box 151109, San Rafael, California 94915-1109
Voice: (415) 472-3960 • FAX: (415) 472-3961
execdir@anco-online.org • www.anco-online.org

Vol. 17, No. 3

February 9th, 2018

The *ANCO FAX News* focuses on ANCO's core activities—advocacy, clinical and professional education, and *Association* and membership news. While membership mailings and e-mail/FAX broadcasts continue, the *ANCO FAX News* summarizes this information in a regular forum of important news to members. Contact the ANCO office for additional information regarding any item published in the *ANCO FAX News*. Find the *ANCO FAX News* online at www.anco-online.org/pubs.html.

In this issue:

- Right-to-Try Legislation & ESA NCD
- ASCO JOP Examines Pathways
- *Best of SABCS San Francisco*
- *Multidisciplinary Management of Cancers*

The *ANCO FAX News* is FAXed to Individual Member practices, and e-mailed to Group, Institutional, and Corporate (contacts) Members.

The next regular *ANCO FAX News* will be published on February 23rd. Send your comments or contributions to ANCO, P.O. Box 151109, San Rafael, CA 94915-1109; Voice: (415) 472-3960; FAX: (415) 472-3961; execdir@anco-online.org.

The *ANCO FAX News* has information for every member of your practice or organization. Pass it along!

- Physician Members
- Nurses & Office Managers
- Office Staff
- Colleagues & Representatives

The *Association of Northern California Oncologists* (ANCO) is an association of hematologists/oncologists dedicated to promoting high professional standards of cancer care by providing a forum for the exchange of ideas, data, and knowledge.

The material contained in the *ANCO FAX News* is intended as general information for ANCO members. Because diagnostic, treatment, contracting, coding, and billing decisions should be made on a case-by-case basis, any such information contained in the *ANCO FAX News* may not apply in any given situation. Members are encouraged to contact their own consultants or advisors to obtain specific advice on matters relating to contracting, coding, and billing. The information contained in the *ANCO FAX News* should not be used as a substitute for such advice.

ADVOCACY

[Editor's Note: ANCO is a member of the Association of Community Cancer Centers (ACCC) and a state/regional affiliate of the American Society of Clinical Oncology (ASCO). ANCO and the Medical Oncology Association of Southern California (MOASC) are members of the California Medical Association's (CMA) Council on Legislation, House of Delegates, and specialty delegation. ANCO meets regularly with these and other organizations to discuss issues of importance to hematology/oncology practices and people living with cancer. We continually seek input from members on agenda items for these meetings. Send your issues to the ANCO office.]

ACCC, ASCO, ASH, COA, and National Legislative & Regulatory Issues

ASCO is one of nearly 40 organizations urging *Members of Congress* to oppose two “right-to-try” (RTT) bills currently under consideration. In a letter to *House* leadership, the organizations expressed their support for patient access to promising unapproved therapies, but stated that the legislation under consideration would fail to actually expand such access, and more importantly, could do more harm than good to seriously ill patients. Read the letter at www.asco.org/sites/new-www.asco.org/files/content-files/February-2018-Right-to-Try-Coalition-Letter.pdf; read ASCO's policy statement on RTT at www.asco.org/advocacy-policy/asco-in-action/asco-releases-position-statement-access-investigational-drugs.

CMS has sent out an ICD-10 coding update transmittal (#1975) on ESAs (epoetin alfa and darbepoetin alfa) that explicitly stated that “No policy-related changes are included with these updates. Any policy-related changes to NCDs continue to be implemented via the current, long-standing NCD process.” However, confusion reigns regarding:

- The date of adoption—there is contradictory information regarding the effective date of the coding updates in various communications from CMS.
- Codes eliminated—some of the eliminated codes are for on-label indications.

ANCO has asked ASCO and Noridian/JEMAC

for clarification as to coverage changes and impact on oncology-related indications for ESAs. Read Bobbi Buell's analysis at www.anco-online.org/BBESAUpdate.pdf.

CMS has updated its Extreme and Uncontrollable Circumstances Policy for the 2017 Merit-based Incentive Payment System (MIPS) transition year to include counties affected by the California wildfires. For more information, visit www.cms.gov/Medicare/Quality-Payment-Program/Resource-Library/Interim-Final-Rule-with-Comment-fact-sheet.pdf.

CMS has announced that doctors and other eligible clinicians participating in the Quality Payment Program can begin submitting their 2017 performance data using a new system on the Quality Payment Program website (qpp.cms.gov). For a fact sheet on the Quality Payment Program data submission system, please visit www.cms.gov/Medicare/Quality-Payment-Program/Resource-Library/QPP-2017-Data-Submission-Factsheet.pdf.

ASCO and the American Society for Radiation Oncology (ASTRO) have launched their new, joint platform for quality reporting, making it easier for oncologists to comply with Federal government reporting requirements for 2018. The new QOPI Reporting Registry, a Qualified Clinical Data Registry (QCDR), now makes it possible for any practice with at least one active ASCO or ASTRO member to report their quality performance data either electronically or manually, based on their preference. Learn more at www.asco.org/advocacy-policy/asco-in-action/new-ASCO-ASTRO-QOPI-reporting-registry-jan-2018.

ASCO's Quality Oncology Practice Initiative (QOPI) Qualified Clinical Data Registry (QCDR) is available for CMS MIPS reporting. By using the QOPI QCDR for MIPS reporting, practices will be able to report in 2018 to avoid cuts to Medicare reimbursements in 2020. Express your interest in participating in the QOPI QCDR by

e-mailing qopi@asoc.org. Practices will be contacted regarding the necessary steps to begin their on-boarding process. For more information, please visit www.instituteforquality.org/qopi/about/quality-reporting.

ASCO's series of webinars to guide oncology practices to successful quality reporting are available at www.asco.org/macra > MACRA Webinar Series. A recording and the slides from their recent *Quality Payment Program: Preparing for 2018, Surviving in 2017* are now available. **ASCO has developed a MACRA decision tree tool to help oncology practices find precise information on their QPP participation status** at www.asco.org/practice-guidelines/billing-coding-reporting/macra-quality-payment-program/macra-practice-tools/determine-status. For more information and access to ASCO's revamped QPP/MACRA toolkit, educational materials, and resources, go to www.asco.org/macra.

The United States Food and Drug Administration (FDA) has updated its information on the shortage of etoposide and is now reporting that, per *Bristol-Myers Squibb Oncology*, the shortage is due to increased demand. Availability is now estimated at the end of February. The FDA update, including an 800 number to contact BMS, is at www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Etoposide%20Injection&st=c&tab=tabs-1.

ASCO has released its review of leading oncology pathway vendors. *Oncology Clinical Pathways; Charting the Landscape of Pathway Providers*, published in the *Journal of Oncology Practice* (JOP), examines the clinical pathways offered by six commercial vendors using the *Society's* criteria for high-quality clinical pathways. The report found that—with a few exceptions—overall, prominent commercial pathway programs are largely aligned with ASCO's criteria. ASCO's *Criteria for High-Quality Clinical Pathways in Oncology* ([\[pathways\]\(http://www.asco.org/practice-guidelines/cancer-care-initiatives/clinical-pathways\)\), a set of 15 inter-related criteria that provide an overarching framework for assessing pathway programs in the United States, focus on three key areas—development, implementation and use, and analytics. Read the JOP article at \[ascopubs.org/doi/10.1200/JOP.17.00033\]\(http://ascopubs.org/doi/10.1200/JOP.17.00033\).](http://www.asco.org/practice-guidelines/cancer-care-initiatives/clinical-</p>
</div>
<div data-bbox=)

ASCO has provided comments on the latest draft statement on the compounding of medications by physicians by the Federation of State Medical Boards (FSMB), largely reiterating concerns had with the first draft. In the comments, ASCO asks FSMB to reference the *Food and Drug Administration* (FDA) definition of compounding, which excludes the mixing and diluting typically done in medical oncology practices. ASCO also disagrees with FSMB's recommendation of compliance with USP Chapters 797 and 800. Read ASCO's comments at asco1.sharefile.com/share/view/s9cd7becd0894981a?j=39990867&sfmc_sub=933038345&l=18416124_HTML&u=699659188&mid=10831477&cjb=1&et_cid=39990867&et_rid=933038345&linkid=comments.

CMA, MOASC, and State Legislative & Regulatory Issues

ANCO (and MOASC) have joined the *California Medical Association* (CMA) and the *Coalition to Protect Access to Care* in opposing SB562, legislation that would eliminate Medi-Cal, Medicare, all private insurance, and the Covered California exchange in favor of a singular health insurance product provided by the state. SB562 offers no way to pay for the single payer system. Learn more at www.protectaccessca.org/what-s-new/providers-join-forces-to-protect-california-s-health-care-system.

Implementation of California's first-of-its-kind drug pricing legislation (SB17) began on January 1st and the complete roll-out of the legislation will occur over the next 12-18 months. *RunawayRx's* new infographic helps explain what SB17's roll-out will look like,

who will receive notice of price hikes, and when the public can expect to see data on Rx price changes. The infographic is at runawayrx.org/wp-content/uploads/2018/01/CAHP-SB-17-Implementation-Infographic-FINAL.pdf.

CMA Practice Resources (CPR) is a monthly e-mail bulletin from CMA's *Center for Economic Services* that is full of tips and tools to help physicians and their office staff improve practice efficiency and viability. Subscribing to CPR is free and open to anyone, but CMA membership is necessary to access the resources, toolkits, forms, and tools that are located on the members-only CMA website. Please visit www.cmanet.org/cpr to subscribe. The February 2018 edition includes:

- Physicians report loss of patients due to Anthem error
- Noridian implements temporary ICD-10 code fix for mammography and breast biopsy policies
- Anthem dials back modifier 25 payment reduction policy; delays implementation
- Having trouble getting paid correctly under California's out-of-network billing and payment law? CMA can help
- The Coding Corner: The top three E/M documentation problems

Noridian/JEMAC, DHCS/MediCal, & Private Payers

Noridian Administrative Services is the Jurisdiction E (JE) *Medicare Administrative Contractor* (MAC). Jurisdiction E includes California. Regularly review postings at the *Noridian/JEMAC* website at med.noridianmedicare.com/web/jeb. Recent updates include:

- MLN Connects Provider eNews *Announcements*—Therapy Cap Claims Rolling Hold; New Medicare Card: Web Updates; MIPS Clinicians: 2017 Extreme

and Uncontrollable Circumstances Policy; Quality Payment Program: Patient-facing Encounters Resources; Find Medicare FFS Payment Regulations; MIPS: Call for Advancing Care Information Measures and Improvement Activities; Quality Payment Program: Advanced APM Table; Hospice Quality Reporting Program Resources
Events—Low Volume Appeals Settlement Option Call-February 13; What's New With Physician Compare Webinar—February 21 or 22
Publications—Looking for Educational Materials?; Medicare Enrollment Resources Educational Tool-Revised

- InVitro Chemosensitivity & Chemoresistance Assays Draft LCD Published for Review and Comments
- MolDX: Corus CAD Assay Draft LCD Published for Review and Comments
- MolDX: MDS FISH Draft LCD Published for Review and Comments
- NMP and/or IVR Required Use for Claim Status-Effective February 5, 2018
- Opt Out Listings Removed from Noridian Website-Effective January 29, 2018
- EDISS Remittance Advice Process Change
- Therapy Claims Being Held for January 2018
- MolDX: Oncotype DX Genomic Prostate Score for Men with Favorable Intermediate Risk Prostate Cancer Final LCD-Effective March 18, 2018
- February Webinars-Register Now
- Medicare Participating Physician Directory Information

- NMP and/or IVR Required Use for Financial Inquiries-Effective February 5, 2018
- Medicare B News JE January 2018 Bulletin-Now Available
- NMP and/or IVR Enrollment Application Status Search Required Use-Effective February 5, 2018
- Enrollment Application Status Tool
- MolDX Molecular Test Registration and Claims Submission

Forthcoming Noridian/JEMAC meetings/webinars/workshops include:

- Chronic Care Management (CCM) Webinar (February 14, 2018)
- Reopenings Webinar (February 21, 2018)
- Basic Non-Covered Services Webinar (February 28, 2018)

Visit med.noridianmedicare.com/web/job/education/training-events for more information and to register.

Anthem Blue Cross has announced that it would reduce the magnitude of its modifier 25 payment cut from 50% to 25% and would delay implementation until March 1st, 2018. Anthem will be issuing formal guidance to network physicians communicating these changes.

The Anthem Blue Cross Network eUpdate (February 2018) is now available online at https://www11.anthem.com/ca/provider/f5/s3/t3/pw_g330753.pdf?refer=provider.

UnitedHealthcare's Network Bulletin (February 2018) is now available online at www.unitedhealthcareonline.com > Tools & Resources > News & Network Bulletin and features articles on billing for intravenous and subcutaneous immune globulin and Remicade, and changes to prior authorization requirements and coverage criteria for *UnitedHealthcare Commercial*.

EDUCATION

[Editor's Note: ANCO organizes clinical and professional education meetings throughout the year and throughout Northern California.]

Best of SABCS San Francisco

ANCO, in association with the Organizing Committee of the San Antonio Breast Cancer Symposium and Encore Medical Education, hosted the **Best of San Antonio Breast Cancer Symposium San Francisco (Best of SABCS San Francisco)** at **The Claremont Hotel** on **Saturday morning, January 27th**. This program was an enhancement of ANCO's traditional *SABCS Highlights*. Hope S. Rugo, M.D., *UC San Francisco*, was the *Regional Director* for *Best of SABCS San Francisco*. Download the presentations at www.anco-online.org/index.html.

18th Multidisciplinary Management of Cancers: A Case-based Approach

The *18th Multidisciplinary Management of Cancers: A Case-based Approach* returns to the *Silverado Resort and Spa* in Napa on March 16-18th. The meeting is sponsored by the *Association of Northern California Oncologists*, *Stanford Cancer Institute*, *UC Davis Comprehensive Cancer Center*, and the *UCSF Helen Diller Family Comprehensive Cancer Center*. Go to www.multicancers.org for more information including registration. Housing at the *Silverado* resort is now sold out; however, *Silverado* will direct you to a service (www.napavalleyreservations.com; 707-252-1985) that will find accommodations available adjacent to *Silverado*.

Additional Education Meetings

February 13th

For Caregivers: Practical Tips to Cope with your Loved One's Lung Cancer (Part II of Living With Lung Cancer)

CancerCare Connect Education Workshop (www.cancercare.org/connect_workshops)

February 26th

Managing Eye and Vision Changes Related to Cancer Treatments

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

February 28th

Triple Negative Breast Cancer in the African American Community

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 1st

Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem Cell or Bone Marrow

Transplantation: New Treatment Approaches
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 2nd

Update on Clinical Trials: How They Work
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 3rd

The 17th Annual CPIC Breast Cancer Conference
Cancer Prevention Institute of California
San Francisco
(www.cpic.org)

March 9th

Treatment Update on Renal Cell Cancer
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 12th

Advances in the Treatment of Mesothelioma
CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 14th

Update on the Treatment of Bladder Cancer (Part I of Living with Bladder Cancer)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 14-16th

44th Annual Meeting & Cancer Center Business Summit
ACCC
Washington, D.C.

(www.accc-cancer.org/meetings/AM2018.asp?)

March 15th

Updates from the 2017 American Society of Hematology (ASH) Annual Meeting

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

March 21st

For Caregivers: Practical Tips to Cope with Your Loved One's Bladder Cancer (Part II of Living with Bladder Cancer)

CancerCare Connect Education Workshop
(www.cancercare.org/connect_workshops)

Please contact the ANCO office for more information about these meetings.

ASSOCIATION & MEMBERSHIP NEWS, RESOURCES, & BENEFITS

[Editor's Note: All ANCO members are also eligible for several tangible benefits.]

Board of Directors

The ANCO *Board of Directors* meets by teleconference and occasionally in person to discuss issues affecting the *Association*, clinical and professional education, and ways to better serve the membership. *Board* teleconferences/meetings are open to individual physician members. The **next regularly scheduled ANCO Board of Directors teleconference is scheduled for February 27th**. Please call José Luis González, *ANCO Executive Director*, at (415) 472-3960 if you wish to participate in a future teleconference/meeting.

Individual Member News

A current *Directory of Members* is available online at www.anco-online.org/pubs.html as a .pdf document. We urge all ANCO members to download their own edition of *The ANCO Directory of Members*. Please verify your *Directory* entry and contact the ANCO office at execdir@anco-online.org with any corrections, additions, and/or deletions.

Group Member News

ANCO initiated a **Group Membership** in 2008 based on a mutual set of perceived values and benefits and a mutual set of interests. The ANCO *Board* believes that the *Association* and *The Permanente Medical Group* (TPMG) will each receive value from Group Membership.

Come and join the *Permanente* community for the very first **Kaiser Permanente National Oncology Symposium** at the *San Francisco Marriot Marquis Hotel* on April 27-28th. For updates, please visit www.kpsymposia.com.

ANCO initiated a **Multi Site Group Membership** in 2010 to encourage all physicians (medical and radiation oncologists) from multi-site and multidisciplinary practices to join. ANCO thanks *Diablo Valley Oncology & Hematology Medical Group*, *EPIC Care*, *Marin Cancer Care*, *Pacific Cancer Care*, and *Palo Alto Medical Foundation* for their multi site group memberships.

Institutional Member News

ANCO initiated an **Institutional Membership** in 2002. *Department(s) of Hematology and/or Oncology* of accredited, degree granting teaching universities or research institutions are eligible for institutional membership. ANCO thanks the following Institutional Members for their support:

- *Stanford Cancer Center*
- *University of California, Davis, Cancer Center*
- *University of California, San Francisco*

Corporate Member News

ANCO thanks the following **Corporate Members** for their generous support that enables ANCO to provide services to the hematology/oncology community in northern California, and to provide its members and their patients with substantial benefits in the areas of advocacy, education, and information dissemination:

AbbVie • *Agendia* • *Agios Pharmaceuticals*
Alexion Pharmaceuticals
AMGEN • *ARIAD Pharmaceuticals*
Array BioPharma • *Astellas Oncology*
AstraZeneca
Bayer Healthcare Pharmaceuticals
bioTheranostics
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb Oncology
Cardinal Health Specialty Solutions
Celgene • *Clovis Oncology* • *Daiichi Sankyo*
Eisai • *EMD Serono* • *Exelixis*
Foundation Medicine • *Genentech BioOncology*
Genomic Health • *Gilead Sciences*
Guardant Health • *Helsinn Oncology*
Heron Therapeutics • *Incyte*
Janssen Oncology • *Jazz Pharmaceuticals*
Kite Pharmaceuticals • *Lilly Oncology* • *Merck*
nanoString • *Novartis Oncology*
Oncology Supply/ION • *Pfizer Oncology*
Pfizer US Biosimilars • *Pharmacyclics*
Puma Biotechnology • *Sandoz Biopharmaceuticals*
Sanofi Genzyme • *Seattle Genetics*
Taiho Oncology • *Takeda Oncology*
TerSera Therapeutics • *Tesaro*
Teva Oncology

Please visit www.anco-online.org/assistance.html for **Corporate Member drug reimbursement and patient assistance program information**. ANCO encourages all member practices to use this resource and enroll all patients at the start of treatment in all available and appropriate patient assistance programs.

AstraZeneca will host a dinner program entitled *Head to Head Progression-Free Survival Data for Patients who have Progressed After EGFR TKI Therapy* with Hatim Husain, M.D., *Moore's Cancer Center, University of California, San Diego*, on March 17th at *Morimoto Restaurant* in Napa. RSVP to Jason Yonehiro, (415) 205-3699 or jason.yonehiro@astrazeneca.com.

Novartis Oncology informs ANCO that the *United States Food and Drug Administration* has approved Lutathera for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract call gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This is the first time a

radioactive drug, or radiopharmaceutical, has been approved for the treatment of GEP-NETs. Lutathera is indicated for adult patients with somatostatin receptor-positive GEP-NETs.

Clinical Trial News

For the latest clinical trials being offered at ANCO's **Institutional Members**, please visit:

- med.stanford.edu/cancer/trials.html
- ucdmc.ucdavis.edu/cancer/clinical-trials/search/index.html
- cancer.ucsf.edu/clinical-trials/

Publications, Resources, Services, & Surveys

ASCO's *Clinical Affairs Department* provides services, education, and resources to support oncology practices. It offers hands-on assistance in areas such as practice management, quality care assessment and improvement, and efficiency and business intelligence to meet the needs and demands of the current oncology landscape. Resources on the business of oncology, practice management (staffing, technology), practice transformation, and market analysis are available from the *Department*. For more information, visit www.asco.org/practice-guidelines/practice-support.

The **ASCO Guidelines App** is your go-to tool for implementing guideline recommendations into practice. This user-friendly app provides health care providers, patients, and caregivers with the recommended cancer care options for a variety of cancer types. It also includes interactive tools to inform treatment decisions at the point of care, thus increasing the quality of care provided to patients. The app is free to members and nonmembers, kept up to date, and will continue to grow as more guidelines and tools are added. Download the app at www.asco.org/guidelines or www.asco.org/apps.

As part of ASCO's continued efforts to help oncology practices navigate the evolving cancer care delivery system, ASCO is inviting all

practices to participate in the annual *Survey of Oncology Practice Operations*, which looks at the current state of business and operational issues in oncology. Please take the survey before February 23 at www.asco.org/advocacy-policy/asco-in-action/obtain-data-improve-your-practice-2018-survey-oncology?.

ASCO's 2018 *Quality Training Program*, a comprehensive program designed to train oncology health care providers to investigate and implement data-driven quality improvement and manage clinical and non-clinical processes and outcomes, will take place in two locations—Miami and Alexandria. To learn more about and apply to participate in the *Program*, visit www.asco.org/training-education/professional-development/quality-training-program.

ASCO's PracticeNET is a collaborative network in which practices share and receive insights to enhance their business operations and quality of care. PracticeNET is the first initiative of ASCO's *Clinical Affairs Department*. This new initiative uses existing data from your practice management system to offer customizable reports that measure practice-wide and individual performance against a national database of other PracticeNET participants. Learn more and enroll at www.asco.org/practice-guidelines/practice-support/practicenet?et_cid=39764896&et rid=933038345&linkid=Enroll+in+PracticeNET.

ASCO's *Practice Engagement Program* helps administrators, physicians, and other members of the care team navigate ASCO tools, programs, and resources available to help oncology practices respond to the changes occurring in the cancer care delivery system. Building on an array of resources developed to help practices remain viable and thrive during this turbulent period, the new *Practice Engagement Team* will help participating practices learn more about the specific ASCO services and programs that can best support their needs. Learn more at www.asco.org/advocacy-policy/asco-in-action/new-practice-engagement-program.

connects-practices-specific-resources.

ASCO and Innovative Oncology Business Solutions (IOBS) have announced a new collaboration, ASCO COME HOME—an oncology medical home program designed to transition community oncology practices from volume-based to value-based care by structuring reimbursement around the full range of services needed by patients with cancer. ASCO COME HOME will also prepare oncology practices for full implementation of the Quality Payment Program under MACRA. ASCO is currently accepting practices for the fee-based program. For more information, please visit www.asco.org/practice-guidelines/practice-support/asco-consulting-services/asco-come-home.

The January 2018 issue of ASCO's *Journal of Oncology Practice* (JOP) is available online and features articles entitled *Measuring Quality is Complicated; Are Physician Orders for Life-Sustaining Treatments the Answer to the End-of-Life Care Quality Conundrums in Cancer Care?*; and, *Patient-Oncologist Communication: Sharing Decisions in Cancer Care*. Visit jop.ascopubs.org for more information.

The January/February issue of ACCC's *Oncology Issues* includes articles entitled *Piloting a Patient Resource Navigator System*; and, *Adverse Event Management in the Community-Based Immuno-Oncology Clinic*. Visit www.accc-cancer.org/oncology_issues to read this issue.

ACCC's 2018 *Patient Assistance and Reimbursement Guide* is an essential tool for cancer program staff to use in helping patients with issues related to the cost of treatment and in meeting reimbursement challenges. The *Guide* features a list of pharmaceutical and non-pharmaceutical patient assistance programs (PAPs), including directions on how to apply and links to enrollment forms. Visit www.accc-cancer.org/home/learn/publications/patient-assistance-and-reimbursement-guide to access this resource. In addition, ACCC has developed a tool for accessing patient assistance and

reimbursement programs for use on a desktop, table, or mobile device. The *Financial Advocacy Network* (FAN) app is available at accc-fan-app.org.

NCCN has published and/or updated their *Chemotherapy Order Templates, Clinical Practice Guidelines in Oncology, Drugs & Biologics Compendium, Evidence Blocks, Guidelines for Patients, Imaging Appropriate Use Criteria, and/or Radiation Therapy Compendium* for: acute myeloid leukemia (V1.2018), anal carcinoma (V1.2018), bladder cancer (V1.2018), chronic myeloid leukemia (V4.2018), colon cancer (V1.2018), ovarian cancer (V5.2017), penile cancer (V1.2018), testicular cancer (V1.2018), thymomas and thymic carcinomas (V1.2018), uterine neoplasms (V1.2018). Go to www.nccn.org for more information.

Individual Membership Dues for 2018

Second notices of membership renewal for 2018 were mailed to all members in early February. If you have not yet done so, then please return your 2018 membership dues to ANCO now to ensure your inclusion in *The ANCO Directory of Members*. Be sure to provide ANCO with your e-mail address and the name(s) and e-mail address(es) of office and/or nurse manager contact(s). Those not renewing their membership by June 30th will be deleted from the *Directory of Members*, and will no longer be eligible for any ANCO benefits. Contact the ANCO office if you do not receive or misplaced your membership dues renewal notice.